No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Oxford Biomedica confirmed on Wednesday that it has received unsolicited takeover approaches from private equity firm EQT.
In a brief statement in response to recent press speculation, the cell and gene therapy company said it is now in preliminary discussions with EQT "to explore whether a proposal can be made at a level that the board would be minded to recommend".
"The discussions follow earlier unsolicited proposals from EQT regarding a possible acquisition of OXB," it said. "The board of OXB, together with its advisers, carefully considered the earlier proposals and rejected them on the basis that they undervalued OXB and its prospects."
The company added that there can be no certainty that any firm offer will be made nor as to the terms on which any firm offer might be made.
Under UK takeover rules, EQT has until 1700 GMT on 11 February to either announce a firm intention to make an offer or walk away.
Oxford Biomedica shares closed up 1.3% at 748.71p.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.